Spotlight on Orthopedics
Integrative Solutions to Challenges in Chronic Pain Management – Applying Principles of Pain Management
StartActivity Details
0.25 ABIM MOC point(s)
0.25 ABMS MOC point(s)
Expires: July 21, 2021
Accredited By
Target Audience
This activity is intended for physiatrists and PCPs, those in general internal medicine practices including NPs and PAs.
Learning Objectives
- Describe recent developments in the understanding of pain pathways/pain pathophysiology
- Summarize key points from widely accepted guidelines/standards of care on OA and chronic LBP
- Formulate a plan for ongoing pain assessment that reflects current evidence and incorporates practical tools whenever feasible
- Explain the implications of key efficacy and safety data on emerging treatment options for chronic pain due to OA and LBP
Activity Description
This activity will equip front-line clinicians with evidence-based knowledge and increased competence that can inform the assessment, management and referral of patients with chronic osteoarthritis (OA) pain and lower back pain (LBP).
Statement of Educational Need
There are a vast number of challenges in the proper differentiation, assessment, and management of chronic pain (specifically with osteoarthritis [OA] and low back pain [LBP]), and how key facets of pain pathways/pain pathophysiology can help to inform these assessments. There is a need to increase the knowledge and confidence of physiatrists and PCPs (including internal medicine, NP, and PAs) who manage these patients to know the advances in current and emerging management strategies, including the use of a multimodal approach to therapies. An emphasis for a greater integrated multidisciplinary approach for delivering quality coordinated care within and across settings together, in order to improve pain management and patient care in the community, is also needed.
Faculty
STEERING COMMITTEE
Clinical Professor of Medicine
Division of Rheumatology
David Geffen School of Medicine, UCLA
Los Angeles, CA
- Robin Dore, MD, is a consultant for Amgen, Abbvie, Gilead, Lilly, Radius, and Sanofi. She is on a speaker’s bureau for Amgen, Abbvie, Lilly, Pfizer, Radius, UCB, and Sanofi. She has done research for Amgen, Abbvie, Biogen, Gilead, Lilly, and Pfizer.
Family Physician
Collegeville Family Practice
Medical Director of Health Services
Ursinus College
Collegeville, PA
- Paul Doghramji, MD, FAAFP, has no relevant financial relationships to disclose.
Physical Medicine and Rehabilitation
Orthopaedic Specialty Institute
Orange County, CA
- Michael I. Danto, MD, has no relevant financial relationships to disclose.
MOC REVIEWERS
Theodore Bruno, MD
Chief Medical Officer
The France Foundation
- Theodore Bruno, MD, is a stock shareholder of Allergan. His spouse is an employee of Allergan.
Louis Kuritzky, MD
Family Medicine Residency Program
University of Florida Health
- Louis Kuritzky, MD, is a consultant for Amgen, Allergan, Boehringer Ingelheim Pharmaceuticals, Inc, Lilly, Lundbeck, NovoNordisk, Sanofi, and Shire. In addition, he is on the speaker’s bureau for Amgen.
Conflict of Interest Policy/Disclosure Statement
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
Accreditation Statement
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Physicians
The France Foundation designates this enduring activity for a maximum of
0.25 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
American Board of
Internal Medicine (ABIM)
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to 0.25 Medical
Knowledge MOC points in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider's responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Other American Board of
Medical Specialties (ABMS) Member Boards
Through the American Board of Medical Specialties (“ABMS”) ongoing commitment
to increase access to practice relevant Maintenance of Certification (“MOC”)
Activities through the ABMS Continuing Certification Directory,
“Integrative Solutions to Challenges in Chronic Pain
Management” has met the requirements as a MOC Part II CME Activity
(apply toward general CME requirement) for the following ABMS Member
Boards:
MOC Part II CME Activity
Anesthesiology
Family Medicine
Physical Medicine and Rehabilitation
Psychiatry and Neurology
Radiology
Instructions for Receiving Credit
- There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives and CME/CE information.
- Complete the CME/CE activity
- Complete the online posttest. A score of 100% is required to successfully complete this activity. The participant may take the test until successfully passed.
- Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- Credit documentation/reporting:
-
- If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
- If you are requesting ABIM MOC points, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.
- If you are requesting ABMS MOC points, please alert your board that you completed this activity.
Statement of Commercial Support
This program is supported by an independent education grant funded by Pfizer Inc, in partnership with Lilly USA, LLC.
Disclaimer Statement/Disclosure of Unlabeled Use
TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Contact Information for Questions About the Activity
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.
Activity Details
0.25 ABIM MOC point(s)
0.25 ABMS MOC point(s)
Expires: July 21, 2021
Accredited By
Target Audience
This activity is intended for physiatrists and PCPs, those in general internal medicine practices including NPs and PAs.
Learning Objectives
- Describe recent developments in the understanding of pain pathways/pain pathophysiology
- Summarize key points from widely accepted guidelines/standards of care on OA and chronic LBP
- Formulate a plan for ongoing pain assessment that reflects current evidence and incorporates practical tools whenever feasible
- Explain the implications of key efficacy and safety data on emerging treatment options for chronic pain due to OA and LBP
Activity Description
This activity will equip front-line clinicians with evidence-based knowledge and increased competence that can inform the assessment, management and referral of patients with chronic osteoarthritis (OA) pain and lower back pain (LBP).
Statement of Educational Need
There are a vast number of challenges in the proper differentiation, assessment, and management of chronic pain (specifically with osteoarthritis [OA] and low back pain [LBP]), and how key facets of pain pathways/pain pathophysiology can help to inform these assessments. There is a need to increase the knowledge and confidence of physiatrists and PCPs (including internal medicine, NP, and PAs) who manage these patients to know the advances in current and emerging management strategies, including the use of a multimodal approach to therapies. An emphasis for a greater integrated multidisciplinary approach for delivering quality coordinated care within and across settings together, in order to improve pain management and patient care in the community, is also needed.
Faculty
STEERING COMMITTEE
Clinical Professor of Medicine
Division of Rheumatology
David Geffen School of Medicine, UCLA
Los Angeles, CA
- Robin Dore, MD, is a consultant for Amgen, Abbvie, Gilead, Lilly, Radius, and Sanofi. She is on a speaker’s bureau for Amgen, Abbvie, Lilly, Pfizer, Radius, UCB, and Sanofi. She has done research for Amgen, Abbvie, Biogen, Gilead, Lilly, and Pfizer.
Family Physician
Collegeville Family Practice
Medical Director of Health Services
Ursinus College
Collegeville, PA
- Paul Doghramji, MD, FAAFP, has no relevant financial relationships to disclose.
Physical Medicine and Rehabilitation
Orthopaedic Specialty Institute
Orange County, CA
- Michael I. Danto, MD, has no relevant financial relationships to disclose.
MOC REVIEWERS
Theodore Bruno, MD
Chief Medical Officer
The France Foundation
- Theodore Bruno, MD, is a stock shareholder of Allergan. His spouse is an employee of Allergan.
Louis Kuritzky, MD
Family Medicine Residency Program
University of Florida Health
- Louis Kuritzky, MD, is a consultant for Amgen, Allergan, Boehringer Ingelheim Pharmaceuticals, Inc, Lilly, Lundbeck, NovoNordisk, Sanofi, and Shire. In addition, he is on the speaker’s bureau for Amgen.
Conflict of Interest Policy/Disclosure Statement
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
Accreditation Statement
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Physicians
The France Foundation designates this enduring activity for a maximum of
0.25 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
American Board of
Internal Medicine (ABIM)
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to 0.25 Medical
Knowledge MOC points in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider's responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Other American Board of
Medical Specialties (ABMS) Member Boards
Through the American Board of Medical Specialties (“ABMS”) ongoing commitment
to increase access to practice relevant Maintenance of Certification (“MOC”)
Activities through the ABMS Continuing Certification Directory,
“Integrative Solutions to Challenges in Chronic Pain
Management” has met the requirements as a MOC Part II CME Activity
(apply toward general CME requirement) for the following ABMS Member
Boards:
MOC Part II CME Activity
Anesthesiology
Family Medicine
Physical Medicine and Rehabilitation
Psychiatry and Neurology
Radiology
Instructions for Receiving Credit
- There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives and CME/CE information.
- Complete the CME/CE activity
- Complete the online posttest. A score of 100% is required to successfully complete this activity. The participant may take the test until successfully passed.
- Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- Credit documentation/reporting:
-
- If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
- If you are requesting ABIM MOC points, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.
- If you are requesting ABMS MOC points, please alert your board that you completed this activity.
Statement of Commercial Support
This program is supported by an independent education grant funded by Pfizer Inc, in partnership with Lilly USA, LLC.
Disclaimer Statement/Disclosure of Unlabeled Use
TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Contact Information for Questions About the Activity
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.
Orthopedics Presentations
Immune-Mediated Inflammatory Disease Curbside Consults: RA – What to Do After TNF Failure?
StartActivity Details
Expires: October 18, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is dermatologists, gastroenterologists, rheumatologists, and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases.
Learning Objective
Upon successful completion of this activity, participants should be better able to review the latest clinical evidence regarding tumor necrosis factor inhibitor (TNFi) cycling versus switching strategies after first-line TNFi failure.
Activity Description
In this Curbside Consult video, Drs. Leonard Calabrese and Stanley Cohen discuss strategies for managing RA in a patient after loss of response to first-line TNF inhibitor therapy.
Activity Chair
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosures:
Consulting Fee: AbbVie, Amgen, Bristol Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Kiniksa, Lilly, Pfizer, Sanofi-Regeneron, UCB
Speakers Bureau: AbbVie, Bristol Myers Squibb, Crescendo, Genentech, Horizon, Sanofi, UCB
Faculty
Clinical Professor
Department of Internal Medicine
University of Texas Southwestern Medical School
Co-Director, Division of Rheumatology
Presbyterian Hospital
Co-Medical Director, Metroplex Clinical Research Center
Dallas, TX
Disclosures:
Consulting Fee: AbbVie, Amgen, Genentech, Gilead, Lilly, Pfizer
Contracted Research(Paid to Institution): AbbVie, Amgen, Genentech, Gilead, Lilly, Pfizer
Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosures: No relevant financial relationships to
disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, October 19, 2020 to October 18, 2021.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objective, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by educational grants from AbbVie Inc. and Genentech, Inc.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com.
Activity Details
Expires: October 18, 2021
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is dermatologists, gastroenterologists, rheumatologists, and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases.
Learning Objective
Upon successful completion of this activity, participants should be better able to review the latest clinical evidence regarding tumor necrosis factor inhibitor (TNFi) cycling versus switching strategies after first-line TNFi failure.
Activity Description
In this Curbside Consult video, Drs. Leonard Calabrese and Stanley Cohen discuss strategies for managing RA in a patient after loss of response to first-line TNF inhibitor therapy.
Activity Chair
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosures:
Consulting Fee: AbbVie, Amgen, Bristol Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Kiniksa, Lilly, Pfizer, Sanofi-Regeneron, UCB
Speakers Bureau: AbbVie, Bristol Myers Squibb, Crescendo, Genentech, Horizon, Sanofi, UCB
Faculty
Clinical Professor
Department of Internal Medicine
University of Texas Southwestern Medical School
Co-Director, Division of Rheumatology
Presbyterian Hospital
Co-Medical Director, Metroplex Clinical Research Center
Dallas, TX
Disclosures:
Consulting Fee: AbbVie, Amgen, Genentech, Gilead, Lilly, Pfizer
Contracted Research(Paid to Institution): AbbVie, Amgen, Genentech, Gilead, Lilly, Pfizer
Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
Disclosures: No relevant financial relationships to
disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, faculty, and reviewers involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, October 19, 2020 to October 18, 2021.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objective, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by educational grants from AbbVie Inc. and Genentech, Inc.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com.
Revolutionizing T2T in RA: Future Paradigms with JAK Inhibitors
StartActivity Details
Expires: July 24, 2021
Accredited By
Target Audience
This activity is intended for rheumatologists, internal medicine specialists, nurses, and other allied health-care professionals, as well as patients and caregivers interested in treatment advances for rheumatoid arthritis (RA).
Learning Objectives
Upon completion of this activity, participants will be able to:
- Assess characteristics of patients with RA that may be predictive of poor response to biologic treatment and assess opportunities with novel therapies
- Evaluate clinical efficacy, safety, and tolerability of biologic and small molecule drugs for the treatment of RA
- Implement treat-to-target strategies for refractory patients considerate of disease activity, treatment response, and other patient-specific factors
Activity Description
How can clinicians be assured they have the most up-to-date information for improving their patients’ outcomes in RA care? In this clinical commentary, leading infectious disease expert Kevin Winthrop, MD, MPH, and Rheumatology experts Philip Mease, MD, MACR, and William F.C. Rigby, MD, discuss the latest evidence, safety data, and potential roles with the available and emerging JAK inhibitors, as well as current treat-to-target RA paradigms.
Because the patient plays such a critical role in shared decision-making, this activity will also include patient ambassadors sharing their perspectives, experiences, and treatment goals.
Bonus supplemental material includes:
- Understanding Discordance in RA Care
- Patient Perspectives on Shared Decision-Making
- What Patients with RA Want Their Rheumatologists to Know
- EULAR 2020 RA Updates
Statement of Educational Need
Rheumatoid arthritis (RA) is a debilitating, inflammatory condition that has significant ramifications on a patient’s quality of life, risk for disability, morbidity, and mortality. The range of disease-modifying antirheumatic drugs (DMARDs) has shifted and expanded dramatically for RA over the last 20 years, facilitating the use of a treat-to-target approach. With multiple classes of biologic and targeted therapies now approved for RA and more biosimilars coming to market as patents expire on older biologic agents, therapy decisions are rapidly becoming more complex, and physicians may be struggling to keep up.
As the availability of these novel agents complicates treatment decisions for RA, physicians need to properly evaluate treat-to-target strategies for their patients and therapy selection that should be made in concert with patients, after reviewing their treatment history, route of administration, and lifestyle preferences. In addition, rheumatologists and clinicians who treat or diagnose RA need to enhance their understanding of the latest treatments and best practices to manage their patient populations effectively. Physicians need to take an active approach to apply the current evidence in practice with their RA patients and alleviate the burden the patient faces.
Agenda
Clinical commentary highlights includes:
- Available and emerging JAK inhibitors
- Tactics for patients who may have a poor response to biologic treatment
- Role and adverse event management of small molecule drugs
- The latest treat-to-target paradigms
Chair
Professor,
Division of Infectious Diseases
Schools of Medicine and Public Health
Oregon Health and Science University
Portland, OR
Faculty
Director, Rheumatology Research Division
Swedish Medical Center/Providence-St. Joseph Health
Clinical Professor, University of Washington School of Medicine
Seattle, WA
Professor of Medicine, Microbiology and Immunology
Division of Rheumatology
Vice Chairman, Academic Affairs
Department of Medicine
Dartmouth Medical School
Dartmouth-Hitchcock Medical Center
Lebanon, NH
Patient Ambassadors
Founder, Rheumatoid Arthritis Warrior Community
RAwarrior.com
Founder, Rheumatoid Patient Foundation
Executive Director,
Rheumatoid Patient Foundation
rheum4us.org
Conflict of Interest Policy/Disclosure Statement
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.
The following financial relationships have been provided:
Kevin Winthrop, MD, MPH (Chair)
Sources of Funding for Research: Bristol Myers Squibb and Pfizer Inc.
Consulting Agreements: Abbvie, Galapagos, Gilead Sciences, Inc.,
GlaxoSmithKline, Lilly, Pfizer Inc., Roche, UCB
Philip Mease, MD, MACR (Faculty)
Sources of Funding for Research: Abbvie, Amgen, Bristol Myers Squibb,
Galapagos, Gilead Sciences, Inc., Janssen, Lilly, Novartis, Pfizer Inc., Sun
Pharmaceutical Industries Ltd., UCB
Consulting Agreements: Abbvie, Amgen, Bristol Myers Squibb, Boehringer
Ingelheim, Galapagos, Gilead Sciences, Inc., GlaxoSmithKline, Janssen, Lilly,
Novartis, Pfizer Inc., Sun Pharmaceutical Industries Ltd., UCB
Speakers' Bureau: Abbvie, Amgen, Bristol Myers Squibb, Genentech, Janssen,
Lilly, Novartis, Pfizer Inc., UCB
William F.C. Rigby, MD (Faculty)
Clinical Trials: Abbvie, Bristol Myers Squibb, Gilead Sciences, Inc., Pfizer
Inc.
Consulting Agreements (Occasional): Abbvie, Bristol Myers Squibb, Gilead
Sciences, Inc., Pfizer Inc.
Discussion of Off-Label, Investigational, or Experimental Drug/Device
Use:
Baricitinib, filgotinib, upadacitinib as well as JAK inhibitors under
investigation for RA
Patient Ambassador Disclosures
Kelly O'Neill and Shannon Young, EdD, have no financial relationships.
Accreditation Statement
The
Academy for Continued Healthcare Learning is accredited by the Accreditation
Council for Continuing Medical Education (ACCME) to provide continuing
medical education for physicians.
Designation of Credit
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
(NOTE: Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.)
Instructions for Receiving Credit
This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 80% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
Statement of Commercial Support
Supported by an educational grant from Gilead Sciences, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Contact Information for Questions About the Activity
For questions, contact Michelle Forcier at mforcier@achlcme.org
Activity Details
Expires: July 24, 2021
Accredited By
Target Audience
This activity is intended for rheumatologists, internal medicine specialists, nurses, and other allied health-care professionals, as well as patients and caregivers interested in treatment advances for rheumatoid arthritis (RA).
Learning Objectives
Upon completion of this activity, participants will be able to:
- Assess characteristics of patients with RA that may be predictive of poor response to biologic treatment and assess opportunities with novel therapies
- Evaluate clinical efficacy, safety, and tolerability of biologic and small molecule drugs for the treatment of RA
- Implement treat-to-target strategies for refractory patients considerate of disease activity, treatment response, and other patient-specific factors
Activity Description
How can clinicians be assured they have the most up-to-date information for improving their patients’ outcomes in RA care? In this clinical commentary, leading infectious disease expert Kevin Winthrop, MD, MPH, and Rheumatology experts Philip Mease, MD, MACR, and William F.C. Rigby, MD, discuss the latest evidence, safety data, and potential roles with the available and emerging JAK inhibitors, as well as current treat-to-target RA paradigms.
Because the patient plays such a critical role in shared decision-making, this activity will also include patient ambassadors sharing their perspectives, experiences, and treatment goals.
Bonus supplemental material includes:
- Understanding Discordance in RA Care
- Patient Perspectives on Shared Decision-Making
- What Patients with RA Want Their Rheumatologists to Know
- EULAR 2020 RA Updates
Statement of Educational Need
Rheumatoid arthritis (RA) is a debilitating, inflammatory condition that has significant ramifications on a patient’s quality of life, risk for disability, morbidity, and mortality. The range of disease-modifying antirheumatic drugs (DMARDs) has shifted and expanded dramatically for RA over the last 20 years, facilitating the use of a treat-to-target approach. With multiple classes of biologic and targeted therapies now approved for RA and more biosimilars coming to market as patents expire on older biologic agents, therapy decisions are rapidly becoming more complex, and physicians may be struggling to keep up.
As the availability of these novel agents complicates treatment decisions for RA, physicians need to properly evaluate treat-to-target strategies for their patients and therapy selection that should be made in concert with patients, after reviewing their treatment history, route of administration, and lifestyle preferences. In addition, rheumatologists and clinicians who treat or diagnose RA need to enhance their understanding of the latest treatments and best practices to manage their patient populations effectively. Physicians need to take an active approach to apply the current evidence in practice with their RA patients and alleviate the burden the patient faces.
Agenda
Clinical commentary highlights includes:
- Available and emerging JAK inhibitors
- Tactics for patients who may have a poor response to biologic treatment
- Role and adverse event management of small molecule drugs
- The latest treat-to-target paradigms
Chair
Professor,
Division of Infectious Diseases
Schools of Medicine and Public Health
Oregon Health and Science University
Portland, OR
Faculty
Director, Rheumatology Research Division
Swedish Medical Center/Providence-St. Joseph Health
Clinical Professor, University of Washington School of Medicine
Seattle, WA
Professor of Medicine, Microbiology and Immunology
Division of Rheumatology
Vice Chairman, Academic Affairs
Department of Medicine
Dartmouth Medical School
Dartmouth-Hitchcock Medical Center
Lebanon, NH
Patient Ambassadors
Founder, Rheumatoid Arthritis Warrior Community
RAwarrior.com
Founder, Rheumatoid Patient Foundation
Executive Director,
Rheumatoid Patient Foundation
rheum4us.org
Conflict of Interest Policy/Disclosure Statement
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.
The following financial relationships have been provided:
Kevin Winthrop, MD, MPH (Chair)
Sources of Funding for Research: Bristol Myers Squibb and Pfizer Inc.
Consulting Agreements: Abbvie, Galapagos, Gilead Sciences, Inc.,
GlaxoSmithKline, Lilly, Pfizer Inc., Roche, UCB
Philip Mease, MD, MACR (Faculty)
Sources of Funding for Research: Abbvie, Amgen, Bristol Myers Squibb,
Galapagos, Gilead Sciences, Inc., Janssen, Lilly, Novartis, Pfizer Inc., Sun
Pharmaceutical Industries Ltd., UCB
Consulting Agreements: Abbvie, Amgen, Bristol Myers Squibb, Boehringer
Ingelheim, Galapagos, Gilead Sciences, Inc., GlaxoSmithKline, Janssen, Lilly,
Novartis, Pfizer Inc., Sun Pharmaceutical Industries Ltd., UCB
Speakers' Bureau: Abbvie, Amgen, Bristol Myers Squibb, Genentech, Janssen,
Lilly, Novartis, Pfizer Inc., UCB
William F.C. Rigby, MD (Faculty)
Clinical Trials: Abbvie, Bristol Myers Squibb, Gilead Sciences, Inc., Pfizer
Inc.
Consulting Agreements (Occasional): Abbvie, Bristol Myers Squibb, Gilead
Sciences, Inc., Pfizer Inc.
Discussion of Off-Label, Investigational, or Experimental Drug/Device
Use:
Baricitinib, filgotinib, upadacitinib as well as JAK inhibitors under
investigation for RA
Patient Ambassador Disclosures
Kelly O'Neill and Shannon Young, EdD, have no financial relationships.
Accreditation Statement
The
Academy for Continued Healthcare Learning is accredited by the Accreditation
Council for Continuing Medical Education (ACCME) to provide continuing
medical education for physicians.
Designation of Credit
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
(NOTE: Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.)
Instructions for Receiving Credit
This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 80% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
Statement of Commercial Support
Supported by an educational grant from Gilead Sciences, Inc.
Disclaimer Statement/Disclosure of Unlabeled Use
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Contact Information for Questions About the Activity
For questions, contact Michelle Forcier at mforcier@achlcme.org
Integrative Solutions to Challenges in Chronic Pain Management – Patient Case: Osteoarthritis (OA) of the Knee
StartActivity Details
0.25 ABIM MOC point(s)
0.25 ABMS MOC point(s)
Expires: July 21, 2021
Accredited By
Target Audience
This activity is intended for physiatrists and PCPs, those in general internal medicine practices including NPs and PAs.
Learning Objectives
- Describe recent developments in the understanding of pain pathways/pain pathophysiology
- Summarize key points from widely accepted guidelines/standards of care on OA and chronic LBP
- Formulate a plan for ongoing pain assessment that reflects current evidence and incorporates practical tools whenever feasible
- Explain the implications of key efficacy and safety data on emerging treatment options for chronic pain due to OA and LBP
Activity Description
This activity will review and assess the interventions designed to improve the clinical outcomes of patients with chronic osteoarthritis (OA) pain.
Statement of Educational Need
There are a vast number of challenges in the proper differentiation, assessment, and management of chronic pain (specifically with osteoarthritis [OA] and low back pain [LBP]), and how key facets of pain pathways/pain pathophysiology can help to inform these assessments. There is a need to increase the knowledge and confidence of physiatrists and PCPs (including internal medicine, NP, and PAs) who manage these patients to know the advances in current and emerging management strategies, including the use of a multimodal approach to therapies. An emphasis for a greater integrated multidisciplinary approach for delivering quality coordinated care within and across settings together, in order to improve pain management and patient care in the community, is also needed.
Faculty
STEERING COMMITTEE
Clinical Professor of Medicine
Division of Rheumatology
David Geffen School of Medicine, UCLA
Los Angeles, CA
- Robin Dore, MD, is a consultant for Amgen, Abbvie, Gilead, Lilly, Radius, and Sanofi. She is on a speaker’s bureau for Amgen, Abbvie, Lilly, Pfizer, Radius, UCB, and Sanofi. She has done research for Amgen, Abbvie, Biogen, Gilead, Lilly, and Pfizer.
Family Physician
Collegeville Family Practice
Medical Director of Health Services
Ursinus College
Collegeville, PA
- Paul Doghramji, MD, FAAFP, has no relevant financial relationships to disclose.
Physical Medicine and Rehabilitation
Orthopaedic Specialty Institute
Orange County, CA
- Michael I. Danto, MD, has no relevant financial relationships to disclose.
MOC REVIEWERS
Theodore Bruno, MD
Chief Medical Officer
The France Foundation
- Theodore Bruno, MD, is a stock shareholder of Allergan. His spouse is an employee of Allergan.
Louis Kuritzky, MD
Family Medicine Residency Program
University of Florida Health
- Louis Kuritzky, MD, is a consultant for Amgen, Allergan, Boehringer Ingelheim Pharmaceuticals, Inc, Lilly, Lundbeck, NovoNordisk, Sanofi, and Shire. In addition, he is on the speaker’s bureau for Amgen.
Conflict of Interest Policy/Disclosure Statement
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
Accreditation Statement
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Physicians
The France Foundation designates this enduring activity for a maximum of
0.25 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
American Board of
Internal Medicine (ABIM)
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to 0.25 Medical
Knowledge MOC points in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider's responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Other American Board of
Medical Specialties (ABMS) Member Boards
Through the American Board of Medical Specialties (“ABMS”) ongoing commitment
to increase access to practice relevant Maintenance of Certification (“MOC”)
Activities through the ABMS Continuing Certification Directory,
“Integrative Solutions to Challenges in Chronic Pain
Management” has met the requirements as a MOC Part II CME Activity
(apply toward general CME requirement) for the following ABMS Member
Boards:
MOC Part II CME Activity
Anesthesiology
Family Medicine
Physical Medicine and Rehabilitation
Psychiatry and Neurology
Radiology
Instructions for Receiving Credit
- There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives and CME/CE information.
- Complete the CME/CE activity
- Complete the online posttest. A score of 100% is required to successfully complete this activity. The participant may take the test until successfully passed.
- Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- Credit documentation/reporting:
-
- If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
- If you are requesting ABIM MOC points, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.
- If you are requesting ABMS MOC points, please alert your board that you completed this activity.
Statement of Commercial Support
This program is supported by an independent education grant funded by Pfizer Inc, in partnership with Lilly USA, LLC.
Disclaimer Statement/Disclosure of Unlabeled Use
TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Contact Information for Questions About the Activity
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.
Activity Details
0.25 ABIM MOC point(s)
0.25 ABMS MOC point(s)
Expires: July 21, 2021
Accredited By
Target Audience
This activity is intended for physiatrists and PCPs, those in general internal medicine practices including NPs and PAs.
Learning Objectives
- Describe recent developments in the understanding of pain pathways/pain pathophysiology
- Summarize key points from widely accepted guidelines/standards of care on OA and chronic LBP
- Formulate a plan for ongoing pain assessment that reflects current evidence and incorporates practical tools whenever feasible
- Explain the implications of key efficacy and safety data on emerging treatment options for chronic pain due to OA and LBP
Activity Description
This activity will review and assess the interventions designed to improve the clinical outcomes of patients with chronic osteoarthritis (OA) pain.
Statement of Educational Need
There are a vast number of challenges in the proper differentiation, assessment, and management of chronic pain (specifically with osteoarthritis [OA] and low back pain [LBP]), and how key facets of pain pathways/pain pathophysiology can help to inform these assessments. There is a need to increase the knowledge and confidence of physiatrists and PCPs (including internal medicine, NP, and PAs) who manage these patients to know the advances in current and emerging management strategies, including the use of a multimodal approach to therapies. An emphasis for a greater integrated multidisciplinary approach for delivering quality coordinated care within and across settings together, in order to improve pain management and patient care in the community, is also needed.
Faculty
STEERING COMMITTEE
Clinical Professor of Medicine
Division of Rheumatology
David Geffen School of Medicine, UCLA
Los Angeles, CA
- Robin Dore, MD, is a consultant for Amgen, Abbvie, Gilead, Lilly, Radius, and Sanofi. She is on a speaker’s bureau for Amgen, Abbvie, Lilly, Pfizer, Radius, UCB, and Sanofi. She has done research for Amgen, Abbvie, Biogen, Gilead, Lilly, and Pfizer.
Family Physician
Collegeville Family Practice
Medical Director of Health Services
Ursinus College
Collegeville, PA
- Paul Doghramji, MD, FAAFP, has no relevant financial relationships to disclose.
Physical Medicine and Rehabilitation
Orthopaedic Specialty Institute
Orange County, CA
- Michael I. Danto, MD, has no relevant financial relationships to disclose.
MOC REVIEWERS
Theodore Bruno, MD
Chief Medical Officer
The France Foundation
- Theodore Bruno, MD, is a stock shareholder of Allergan. His spouse is an employee of Allergan.
Louis Kuritzky, MD
Family Medicine Residency Program
University of Florida Health
- Louis Kuritzky, MD, is a consultant for Amgen, Allergan, Boehringer Ingelheim Pharmaceuticals, Inc, Lilly, Lundbeck, NovoNordisk, Sanofi, and Shire. In addition, he is on the speaker’s bureau for Amgen.
Conflict of Interest Policy/Disclosure Statement
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
Accreditation Statement
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Physicians
The France Foundation designates this enduring activity for a maximum of
0.25 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
American Board of
Internal Medicine (ABIM)
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to 0.25 Medical
Knowledge MOC points in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider's responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Other American Board of
Medical Specialties (ABMS) Member Boards
Through the American Board of Medical Specialties (“ABMS”) ongoing commitment
to increase access to practice relevant Maintenance of Certification (“MOC”)
Activities through the ABMS Continuing Certification Directory,
“Integrative Solutions to Challenges in Chronic Pain
Management” has met the requirements as a MOC Part II CME Activity
(apply toward general CME requirement) for the following ABMS Member
Boards:
MOC Part II CME Activity
Anesthesiology
Family Medicine
Physical Medicine and Rehabilitation
Psychiatry and Neurology
Radiology
Instructions for Receiving Credit
- There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives and CME/CE information.
- Complete the CME/CE activity
- Complete the online posttest. A score of 100% is required to successfully complete this activity. The participant may take the test until successfully passed.
- Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- Credit documentation/reporting:
-
- If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
- If you are requesting ABIM MOC points, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.
- If you are requesting ABMS MOC points, please alert your board that you completed this activity.
Statement of Commercial Support
This program is supported by an independent education grant funded by Pfizer Inc, in partnership with Lilly USA, LLC.
Disclaimer Statement/Disclosure of Unlabeled Use
TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Contact Information for Questions About the Activity
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.
Integrative Solutions to Challenges in Chronic Pain Management – Applying Principles of Pain Management
StartActivity Details
0.25 ABIM MOC point(s)
0.25 ABMS MOC point(s)
Expires: July 21, 2021
Accredited By
Target Audience
This activity is intended for physiatrists and PCPs, those in general internal medicine practices including NPs and PAs.
Learning Objectives
- Describe recent developments in the understanding of pain pathways/pain pathophysiology
- Summarize key points from widely accepted guidelines/standards of care on OA and chronic LBP
- Formulate a plan for ongoing pain assessment that reflects current evidence and incorporates practical tools whenever feasible
- Explain the implications of key efficacy and safety data on emerging treatment options for chronic pain due to OA and LBP
Activity Description
This activity will equip front-line clinicians with evidence-based knowledge and increased competence that can inform the assessment, management and referral of patients with chronic osteoarthritis (OA) pain and lower back pain (LBP).
Statement of Educational Need
There are a vast number of challenges in the proper differentiation, assessment, and management of chronic pain (specifically with osteoarthritis [OA] and low back pain [LBP]), and how key facets of pain pathways/pain pathophysiology can help to inform these assessments. There is a need to increase the knowledge and confidence of physiatrists and PCPs (including internal medicine, NP, and PAs) who manage these patients to know the advances in current and emerging management strategies, including the use of a multimodal approach to therapies. An emphasis for a greater integrated multidisciplinary approach for delivering quality coordinated care within and across settings together, in order to improve pain management and patient care in the community, is also needed.
Faculty
STEERING COMMITTEE
Clinical Professor of Medicine
Division of Rheumatology
David Geffen School of Medicine, UCLA
Los Angeles, CA
- Robin Dore, MD, is a consultant for Amgen, Abbvie, Gilead, Lilly, Radius, and Sanofi. She is on a speaker’s bureau for Amgen, Abbvie, Lilly, Pfizer, Radius, UCB, and Sanofi. She has done research for Amgen, Abbvie, Biogen, Gilead, Lilly, and Pfizer.
Family Physician
Collegeville Family Practice
Medical Director of Health Services
Ursinus College
Collegeville, PA
- Paul Doghramji, MD, FAAFP, has no relevant financial relationships to disclose.
Physical Medicine and Rehabilitation
Orthopaedic Specialty Institute
Orange County, CA
- Michael I. Danto, MD, has no relevant financial relationships to disclose.
MOC REVIEWERS
Theodore Bruno, MD
Chief Medical Officer
The France Foundation
- Theodore Bruno, MD, is a stock shareholder of Allergan. His spouse is an employee of Allergan.
Louis Kuritzky, MD
Family Medicine Residency Program
University of Florida Health
- Louis Kuritzky, MD, is a consultant for Amgen, Allergan, Boehringer Ingelheim Pharmaceuticals, Inc, Lilly, Lundbeck, NovoNordisk, Sanofi, and Shire. In addition, he is on the speaker’s bureau for Amgen.
Conflict of Interest Policy/Disclosure Statement
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
Accreditation Statement
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Physicians
The France Foundation designates this enduring activity for a maximum of
0.25 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
American Board of
Internal Medicine (ABIM)
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to 0.25 Medical
Knowledge MOC points in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider's responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Other American Board of
Medical Specialties (ABMS) Member Boards
Through the American Board of Medical Specialties (“ABMS”) ongoing commitment
to increase access to practice relevant Maintenance of Certification (“MOC”)
Activities through the ABMS Continuing Certification Directory,
“Integrative Solutions to Challenges in Chronic Pain
Management” has met the requirements as a MOC Part II CME Activity
(apply toward general CME requirement) for the following ABMS Member
Boards:
MOC Part II CME Activity
Anesthesiology
Family Medicine
Physical Medicine and Rehabilitation
Psychiatry and Neurology
Radiology
Instructions for Receiving Credit
- There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives and CME/CE information.
- Complete the CME/CE activity
- Complete the online posttest. A score of 100% is required to successfully complete this activity. The participant may take the test until successfully passed.
- Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- Credit documentation/reporting:
-
- If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
- If you are requesting ABIM MOC points, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.
- If you are requesting ABMS MOC points, please alert your board that you completed this activity.
Statement of Commercial Support
This program is supported by an independent education grant funded by Pfizer Inc, in partnership with Lilly USA, LLC.
Disclaimer Statement/Disclosure of Unlabeled Use
TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Contact Information for Questions About the Activity
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.
Activity Details
0.25 ABIM MOC point(s)
0.25 ABMS MOC point(s)
Expires: July 21, 2021
Accredited By
Target Audience
This activity is intended for physiatrists and PCPs, those in general internal medicine practices including NPs and PAs.
Learning Objectives
- Describe recent developments in the understanding of pain pathways/pain pathophysiology
- Summarize key points from widely accepted guidelines/standards of care on OA and chronic LBP
- Formulate a plan for ongoing pain assessment that reflects current evidence and incorporates practical tools whenever feasible
- Explain the implications of key efficacy and safety data on emerging treatment options for chronic pain due to OA and LBP
Activity Description
This activity will equip front-line clinicians with evidence-based knowledge and increased competence that can inform the assessment, management and referral of patients with chronic osteoarthritis (OA) pain and lower back pain (LBP).
Statement of Educational Need
There are a vast number of challenges in the proper differentiation, assessment, and management of chronic pain (specifically with osteoarthritis [OA] and low back pain [LBP]), and how key facets of pain pathways/pain pathophysiology can help to inform these assessments. There is a need to increase the knowledge and confidence of physiatrists and PCPs (including internal medicine, NP, and PAs) who manage these patients to know the advances in current and emerging management strategies, including the use of a multimodal approach to therapies. An emphasis for a greater integrated multidisciplinary approach for delivering quality coordinated care within and across settings together, in order to improve pain management and patient care in the community, is also needed.
Faculty
STEERING COMMITTEE
Clinical Professor of Medicine
Division of Rheumatology
David Geffen School of Medicine, UCLA
Los Angeles, CA
- Robin Dore, MD, is a consultant for Amgen, Abbvie, Gilead, Lilly, Radius, and Sanofi. She is on a speaker’s bureau for Amgen, Abbvie, Lilly, Pfizer, Radius, UCB, and Sanofi. She has done research for Amgen, Abbvie, Biogen, Gilead, Lilly, and Pfizer.
Family Physician
Collegeville Family Practice
Medical Director of Health Services
Ursinus College
Collegeville, PA
- Paul Doghramji, MD, FAAFP, has no relevant financial relationships to disclose.
Physical Medicine and Rehabilitation
Orthopaedic Specialty Institute
Orange County, CA
- Michael I. Danto, MD, has no relevant financial relationships to disclose.
MOC REVIEWERS
Theodore Bruno, MD
Chief Medical Officer
The France Foundation
- Theodore Bruno, MD, is a stock shareholder of Allergan. His spouse is an employee of Allergan.
Louis Kuritzky, MD
Family Medicine Residency Program
University of Florida Health
- Louis Kuritzky, MD, is a consultant for Amgen, Allergan, Boehringer Ingelheim Pharmaceuticals, Inc, Lilly, Lundbeck, NovoNordisk, Sanofi, and Shire. In addition, he is on the speaker’s bureau for Amgen.
Conflict of Interest Policy/Disclosure Statement
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.
Accreditation Statement
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Physicians
The France Foundation designates this enduring activity for a maximum of
0.25 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
American Board of
Internal Medicine (ABIM)
Successful completion of this CME activity, which includes participation in
the evaluation component, enables the participant to earn up to 0.25 Medical
Knowledge MOC points in the American Board of Internal Medicine's (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider's responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Other American Board of
Medical Specialties (ABMS) Member Boards
Through the American Board of Medical Specialties (“ABMS”) ongoing commitment
to increase access to practice relevant Maintenance of Certification (“MOC”)
Activities through the ABMS Continuing Certification Directory,
“Integrative Solutions to Challenges in Chronic Pain
Management” has met the requirements as a MOC Part II CME Activity
(apply toward general CME requirement) for the following ABMS Member
Boards:
MOC Part II CME Activity
Anesthesiology
Family Medicine
Physical Medicine and Rehabilitation
Psychiatry and Neurology
Radiology
Instructions for Receiving Credit
- There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives and CME/CE information.
- Complete the CME/CE activity
- Complete the online posttest. A score of 100% is required to successfully complete this activity. The participant may take the test until successfully passed.
- Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- Credit documentation/reporting:
-
- If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
- If you are requesting ABIM MOC points, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.
- If you are requesting ABMS MOC points, please alert your board that you completed this activity.
Statement of Commercial Support
This program is supported by an independent education grant funded by Pfizer Inc, in partnership with Lilly USA, LLC.
Disclaimer Statement/Disclosure of Unlabeled Use
TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Contact Information for Questions About the Activity
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.